Adomas Bunevicius1,2,3,4, Julie Miller5,6,7, Michael Parsons5,6,8. 1. Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA. a.bunevicius@yahoo.com. 2. Harvard Medical School, Boston, MA, USA. a.bunevicius@yahoo.com. 3. Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania. a.bunevicius@yahoo.com. 4. Department of Neurosurgery, University of Virginia, 1 Hospital Dr., Charlottesville, VA, 22903, USA. a.bunevicius@yahoo.com. 5. Harvard Medical School, Boston, MA, USA. 6. Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA. 7. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. 8. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Abstract
PURPOSE OF REVIEW: Isocitrate dehydrogenase (IDH) mutation status has important prognostic implications in glioma patients, with IDH wild-type (IDH-WT) gliomas being associated with worse prognosis and shorter survival when compared with IDH mutant (IDH-mut) gliomas. Optimization of quality of life is a priority in the management of glioma patients. The goal of this systematic review was to identify studies that explored the association of IDH mutation status with patient-reported outcomes (PROs) and cognitive functioning of glioma patients. RECENT FINDINGS: Studies that evaluated the association of IDH mutation status with PROs and/or cognitive functioning of glioma patients were identified from the Pubmed/MEDLINE, Clarivate analytics, and Google Scholar databases. Eight studies (7 journal articles and 2 conference abstracts) with a total of 658 low-grade glioma and high-grade glioma patients investigated the association of cognitive functioning and/or QoL with IDH status. IDH-WT status was associated with greater cognitive impairment relative to IDH-Mut status in three studies, while one study did not find the association between IDH status and perioperative cognitive functioning. One study reported worse postoperative cognitive functioning patients with IDH-WT vs. IDH-mut gliomas. In one study, IDH-WT status was linked to greater impairment on physical and communication functioning after surgery. IDH-WT gliomas are associated with greater cognitive burden than IDH-Mut tumors. The association of IDH status with QoL remains less clear. Assessment of IDH status should be considered when evaluating QoL and cognitive complaints of glioma patients. Further studies linking glioma molecular phenotypes with PROs and cognitive functioning are encouraged.
PURPOSE OF REVIEW: Isocitrate dehydrogenase (IDH) mutation status has important prognostic implications in gliomapatients, with IDH wild-type (IDH-WT) gliomas being associated with worse prognosis and shorter survival when compared with IDH mutant (IDH-mut) gliomas. Optimization of quality of life is a priority in the management of gliomapatients. The goal of this systematic review was to identify studies that explored the association of IDH mutation status with patient-reported outcomes (PROs) and cognitive functioning of gliomapatients. RECENT FINDINGS: Studies that evaluated the association of IDH mutation status with PROs and/or cognitive functioning of gliomapatients were identified from the Pubmed/MEDLINE, Clarivate analytics, and Google Scholar databases. Eight studies (7 journal articles and 2 conference abstracts) with a total of 658 low-grade glioma and high-grade gliomapatients investigated the association of cognitive functioning and/or QoL with IDH status. IDH-WT status was associated with greater cognitive impairment relative to IDH-Mut status in three studies, while one study did not find the association between IDH status and perioperative cognitive functioning. One study reported worse postoperative cognitive functioning patients with IDH-WT vs. IDH-mut gliomas. In one study, IDH-WT status was linked to greater impairment on physical and communication functioning after surgery. IDH-WT gliomas are associated with greater cognitive burden than IDH-Mut tumors. The association of IDH status with QoL remains less clear. Assessment of IDH status should be considered when evaluating QoL and cognitive complaints of gliomapatients. Further studies linking glioma molecular phenotypes with PROs and cognitive functioning are encouraged.
Entities:
Keywords:
Cognitive functioning; Glioma; Isocitrate dehydrogenase; Patient-reported outcomes; Quality of life
Authors: Adomas Bunevicius; Stylianos Pikis; Douglas Kondziolka; Dev N Patel; Kenneth Bernstein; Erik P Sulman; Cheng-Chia Lee; Huai-Che Yang; Violaine Delabar; David Mathieu; Christopher P Cifarelli; David E Arsanious; Basem A Dahshan; Joshua S Weir; Herwin Speckter; Angel Mota; Manjul Tripathi; Narendra Kumar; Ronald E Warnick; Selcuk Peker; Yavuz Samanci; Gene Barnett; Farid El Hefnawi; Ghusn Al Sideiri; Jason Sheehan Journal: J Neurooncol Date: 2021-11-19 Impact factor: 4.130
Authors: Ingo K Mellinghoff; Susan M Chang; Kurt A Jaeckle; Martin van den Bent Journal: Hematol Oncol Clin North Am Date: 2021-10-25 Impact factor: 2.861